Clinical Trials

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02737774 2020-07-01

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

60 enrolled

Adenocarcinoma of Lung

NCT02726568 2019-02-19

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03754530 2018-11-27

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

162 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03749213 2018-11-21

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

36 enrolled

EGF-R Positive Non-Small Cell Lung Cancer

NCT03349203 2018-07-18

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

60 enrolled

EGF-R Positive Non-Small Cell Lung Cancer

NCT03396185 2018-07-18

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03151161 2018-06-07

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

118 enrolled

Lung Neoplasms

NCT03346811 2017-11-17

CHALLENGE

120 enrolled

Plasma EGFR Mutation-positive Lung Cancer

NCT01963195 2017-05-08

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

Drug-Related Side Effects and Adverse Reactions

NCT03123484 2017-04-21

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02960607 2016-11-18

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02961270 2016-11-11

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Carcinoma, Non-Small-Cell Lung

NCT02738983 2016-04-14

RT Plus EGFR-TKI for Wild-type NSCLC

22 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02375581 2016-03-22

Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer

130 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT01707329 2015-09-09

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01843647 2015-07-15

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02062515 2015-07-15

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

Carcinoma, Non-Small-Cell Lung

NCT02027090 2015-05-22

High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease

64 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02430974 2015-04-30

Chemotherapy of NSCLC With or Without Icotinib

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02407366 2015-04-02

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02375022 2015-03-24

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

10 enrolled

Lung Neoplasms

NCT02009605 2015-03-05

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

Squamous Cell Carcinoma of Lung

NCT02272127 2014-10-22

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

100 enrolled

NSCLC

NCT02191059 2014-07-31

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01688713 2012-09-20

Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer